Last Updated on January 14, 2024 by The Health Master
In a bid to improve treatment outcomes of multidrug-resistant tuberculosis (MDR TB) in the country, the Indian Council of Medical Research (ICMR) will conduct clinical trials to evaluate new TB drug regimens for MDR TB.
In this regard, the apex research organization in the country has now invited expression of interest (EOI) from government hospitals, medical colleges, research institutions / organizations, and private hospitals and practitioners for conducting studies on the effectiveness of reduced dosage of Linezolid in modified BPaL (bedaquiline, pretomanid, and linezolid regimen with or without MIP (mycobacterium indicus pranii) among MDR TB / rifampicin resistance (RR) patients in India.
MDR TB is caused by an organism that is resistant to at least isoniazid and rifampin, the two most potent TB drugs. These drugs are used to treat all persons with TB disease.
Globally, India bears the burden of the highest prevalence of both TB and MDR TB. As the country struggles to meet its ambitious goal of becoming TB-free by 2025, MDR TB is especially a public health concern and a challenge.
India is a signatory to the WHO Global End TB Strategy, which was approved by the World Health Assembly in May 2014. The strategy called for a 90 per cent reduction in TB incidence and mortality by 2035 and an elimination of catastrophic health expenditure.
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months.
Linezolid, a new antibiotic with activity against mycobacterium tuberculosis, is recommended by the WHO to treat drug resistant tuberculosis as a medicine with “unclear efficacy.”
Several studies suggest that linezolid is poorly tolerated because of the side effects of diarrhoea, constipation, nausea, vomiting, headaches, vision disturbances, flu symptoms, discoloured tongue, and yeast infections.
Other side effects include anaemia, peripheral neuropathy, bone marrow suppression and lactic acidosis.
The optimal dosage for linezolid remains unclear. It is generally prescribed at 600 mg daily or twice daily.
To reduce side effects, ICMR has geared up to conduct a study on the effectiveness of a reduced dosage of Linezolid in a modified BPaL regimen.
It invited application from interested investigators/institutes for participation in the study. The last date for submitting applications is February 22, 2022.
Police protection sought for Drugs Control Officers
USFDA gives nod to Lupin for sNDA for Solosec
India reports outbreak of H5N1 Bird Flu Virus
USFDA gives nod to this Molecule to treat retinal vascular diseases
Govt recommends continuation of anti-dumping duty on import of Amoxycillin
Drug recall: Red Mammoth capsules recalled due to this reason
Molnupiravir effective against Omicron, could reduce deaths: Study
Pharmacists oppose draft amendment allowing class12th pass outs to sell Medical devices
0.31% of drug samples tested in 2020-21 declared as spurious or adulterated
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
